This evidence shows that hydroxychloroquine plays a role in improving obesity-induced lipotoxicity and insulin resistance though the peroxisome proliferator-activated receptor gamma pathway. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.